Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Federica Cicchiello"'
Autor:
Pierluigi di Mauro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 6, Iss , Pp 100167- (2022)
Human epidermal growth factor receptor 2 (HER2) represents a crucial drug target in breast cancer treatment. Currently, several agents that target HER2 are available, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhi
Externí odkaz:
https://doaj.org/article/bb7c80adb05f470aa7de8732da1c80e5
Autor:
Annalisa Zeppellini, Stefania Galimberti, Biagio Eugenio Leone, Claudia Pacifico, Francesca Riva, Federica Cicchiello, Serena Capici, Claudia Maggioni, Luca Sala, Marina Elena Cazzaniga
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between prim
Externí odkaz:
https://doaj.org/article/3fdb9467578f4f46bbc742f0878bda7b
Autor:
Viola Cogliati, Serena Capici, Francesca Fulvia Pepe, Pierluigi di Mauro, Francesca Riva, Federica Cicchiello, Claudia Maggioni, Nicoletta Cordani, Maria Grazia Cerrito, Marina Elena Cazzaniga
Publikováno v:
Life, Vol 12, Iss 3, p 378 (2022)
CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy aft
Externí odkaz:
https://doaj.org/article/b7618c5ae881493ea7f0be0c0cd91cc7
Autor:
Marco Meazza Prina, Irene Gotuzzo, Marina Elena Cazzaniga, Elisabetta De Bernardi, Pietro Cafaro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Federica Cicchiello, Francesca Riva, Nicoletta Cordani, Maria Grazia Cerrito, Elia Anna Turolla, Claudio Landoni, Federica Elisei, Cinzia Crivellaro, Leonardo Virdone, Lavinia Monaco, Alessandro Guidi, Luca Guerra
Publikováno v:
Cancer Research. 83:P6-01
Background: MBC is an incurable disease and chemotherapy (CHT) represents one option of treatment upfront, in TNBC pts, or at failure of an endocrine therapy + targeted agents in HR+ ones. mCHT was extensively studied in different types of ABC pts an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51bc443ab817fc31ad025a232bc8fba9
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-42
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-42
Autor:
Miki Scaravaglio, Antonio Ciaccio, Alice Laffusa, Martina Lucà, Salvatore Longo, Martina Manna, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga, Diego Cortinovis, Pietro Invernizzi
Publikováno v:
Journal of Hepatology. 77:S404-S405
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa2c9b7fdf618ce9cb1cd85c4fb7b6cd
https://doi.org/10.1016/s0168-8278(22)01153-9
https://doi.org/10.1016/s0168-8278(22)01153-9
Autor:
Federica Cicchiello, Marina Elena Cazzaniga, Luca Sala, Annalisa Zeppellini, Biagio Eugenio Leone, Stefania Galimberti, Serena Capici, Francesca Riva, Claudia Maggioni, Claudia Pacifico
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a66fe4c3d124056f94a8b4aba2ea069
https://pubmed.ncbi.nlm.nih.gov/33691674
https://pubmed.ncbi.nlm.nih.gov/33691674
Autor:
Francesca Riva, I Manfrida, S Baroni, Federica Cicchiello, Paolo Bidoli, Paolo Lissoni, D. Pelizzoni, S Malandrin, L Vigorè, Marina Elena Cazzaniga, B Brando
Publikováno v:
Cancer Research. 77:P2-04
BACKGROUND In cancer patients, the accumulation of Tregs is associated with tumor progression and the suppression of anti-tumor immune response. Metronomic cyclophosphamide (mCTX) induces a profound and selective reduction of circulating Tregs, where
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62ae8bba292741cb2e7a3e8b7c5dda70
https://doi.org/10.1158/1538-7445.sabcs16-p2-04-05
https://doi.org/10.1158/1538-7445.sabcs16-p2-04-05
Autor:
Paolo Bidoli, Diego Cortinovis, Annalisa Valentini, Federica Cicchiello, Francesca Riva, Francesca Gallina, Alessandra Crippa, Marina Elena Cazzaniga, Marco Tagliabue
Publikováno v:
Cancer Research. 75:P2-12
BACKGROUND AIs are the milestone adjuvant treatment for postmenopausal early HR+ BC pts. Non-steroidal AIs induce a significant oestrogen deprivation, responsible in approximately 40% of the pts for muscle-skeletal adverse events (MSKs) and for disco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24b3c1455b4c1217769199ecad2b6dad
https://doi.org/10.1158/1538-7445.sabcs14-p2-12-05
https://doi.org/10.1158/1538-7445.sabcs14-p2-12-05
Autor:
Federica Cicchiello, Monica Giordano, Mariangela Ciccarese, L. Zanlorenzi, M. Nicolini, L. Scaltriti, Laura Cortesi, Eliana Rulli, Marina Cazzaniga, Lorenzo Legramandi, E. Biraghi, Claudio Verusio, S. Della Torre, E. Casini, A. Ferzi, A. Gambaro, F. Villa
Publikováno v:
International Journal of Breast Cancer
International Journal of Breast Cancer, Vol 2017 (2017)
International Journal of Breast Cancer, Vol 2017 (2017)
Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3c62ec4334aae4f55d12bb53536957
https://pubmed.ncbi.nlm.nih.gov/29333297
https://pubmed.ncbi.nlm.nih.gov/29333297
Autor:
Federica Cicchiello, Francesco Agustoni, Stefania Canova, Maria Ida Abbate, Giampaolo Bianchini, Paolo Bidoli, Diego Cortinovis
Introduction In spite of the progress in the treatment of non-small-cell lung cancer (NSCLC), the majority of patients with advanced disease still receive chemotherapy. Gemcitabine alone or combined with a platinum compound is a valid option. Thrombo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3cf1de794d7e0d6fb7d6567381929e0
http://hdl.handle.net/10281/260628
http://hdl.handle.net/10281/260628
